By Ethan Covey
A mixed-dose combination of bictegravir, emtricitabine and tenofovir has demonstrated noninferiority in a recently completed phase 3 trial in HIV-positive patients.
The regimen, which is produced by Gilead Sciences, was found to be safe, well tolerated and noninferior to coformulated dolutegravir, abacavir and lamivudine (Triumeq, Viiv Healthcare) (Lancet 2017 Aug 31. [Epub ahead of print]).